Affinity Asset Advisors »

Elevation Oncology shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Elevation Oncology (ELEV) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Elevation Oncology

Tip: Access up to 7 years of quarterly data

All positions including Elevation Oncology held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Elevation Oncology by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-03-31 $6.5M 1.3M 5.13

More positions owned by Affinity Asset Advisors

Spdr Ser Tr S&p Biotech Put Option (XBI)
Teva Pharmaceutical Inds Sponsored Ads Call Option (TEVA)
Moderna Put Option (MRNA)
Apogee Therapeutics (APGE)
Xenon Pharmaceuticals (XENE)
Madrigal Pharmaceuticals (MDGL)
Crinetics Pharmaceuticals In (CRNX)
Autolus Therapeutics Spon Ads (AUTL)
Celldex Therapeutics Com New (CLDX)
Arcellx Common Stock (ACLX)
Vera Therapeutics Cl A (VERA)
Inozyme Pharma (INZY)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Kura Oncology (KURA)
Spyre Therapeutics Com New (SYRE)

View all positions for Affinity Asset Advisors

Top funds holding Elevation Oncology

Farallon Capital Management
Point72 Asset Management
Tang Capital Management
Balyasny Asset Management
Aisling Capital Management
venBio Partners
Braidwell
Darwin Global Management
BVF
Citadel Advisors
Vanguard Group
Artal Group
Hudson Bay Capital Management
Palo Alto Investors
Affinity Asset Advisors

View all funds holding Elevation Oncology